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Abstract 
The purpose of this thesis is to explore the conjugation of biomolecules to 
platinum(IV) compounds. Ever since the serendipitous discovery that cisplatin has 
cytotoxic properties in the 1970’s, research has focused on both understanding the mode 
of action and making new potential drugs that have more desirable properties than 
cisplatin. Oxidizing cisplatin to platinum(IV) allows for the tethering of amines that can 
be used to target cancer cells. 
The first chapter is a brief introduction on the scope of platinum compounds that 
have been made. It also provides general background on the proposed mode of action. 
The second chapter adapts the knowledge of making cisplatin derived 
platinum(IV) complexes that are able to conjugate biomolecules, and adapts it to a second 
generation platinum drug, carboplatin. Furthermore, a method to make mono- or bis- 
substituted conjugates is devised.  
Chapter three describes the tethering of a series of estrogen linkers to oxidized 
derivatives of carboplatin, in hopes of seeing increased toxicity in ER(+) cells. This work 
mimics previous work in our lab which dealt with the tethering of estrogen to oxidized 
derivatives of cisplatin. 
Finally, in chapter four platinum-folate conjugates are described. Because cancer 
cells grossly overexpress folate receptors, tethering folic acid to platinum(IV) is desirable 
as it will allow for increased uptake in cancer cells.  
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This thesis is dedicated to my family. 
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Chapter One: 
 
Introduction 
 10 
  Cisplatin (cis-diamminedichloroplatinum(II)) (Figure 1.1) was first synthesized in 
1845 (1, 2), but the serendipitous discovery that it has anti-tumor properties was not made 
until 1970 (2-4). By 1978 it was approved by the FDA (5), and today it is one of the most 
widely used anti-tumor drugs in the world (6, 7). Testicular cancer, once a death letter, 
now has a cure rate of over 90% (8); cisplatin has also had success in treating ovarian, 
cervical, head and neck, esophageal, and nonsmall lung cancers (9). Despite this success, 
nephrotoxicity, neurotoxicity, and emetogensis have limited the administrable dose of the 
highly potent drug (10). Furthermore, the limited water solubility of cisplatin, the 
relatively narrow range of treatable cancers, and the ability of carcinomas to develop 
resistance have fuelled researchers to develop second generation platinum-based drugs 
(10). Carboplatin (cis-diamminecyclobutanedicarboxylatoplatinum(II)) is a second 
generation drug that has enjoyed success. It is less toxic than cisplatin, allowing for 
higher dosages. Unfortunately, it is only active in treating the same type of tumors as 
cisplatin (10). 
The Biological Target of Cisplatin. Almost immediately, it was realized that DNA 
is the biological target of cisplatin (5, 11). Although platinum can bind to other 
biomolecules including proteins, RNA, phospholipids, and microfilaments (11), DNA is 
its primary biological target.  
Proposed Mode of Action. Cisplatin can enter cells via passive diffusion (12). 
Because the chloride concentration in the cytoplasm is much lower than serum levels (20 
mM verses 100 mM respectively), cisplatin undergoes aquation to form cis-
[Pt(NH3)2Cl(OH2)]+. The positively charged species is trapped inside the cell and can 
subsequently bind to the N7 of purine bases. It predominantly binds to two adjacent 
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guanine bases, forming 1,2 intrastrand cross-links (5). Such a motif distorts the DNA 
double helix, and blocks both replication and transcription (5, 13). Certain proteins 
including high mobility group (HMG) domain proteins recognize and bind the kinked 
DNA, block  nucleotide excision repair (NER), and drive the cell towards apoptosis (5).  
Cisplatin Resistance. Exposing cells to cisplatin results in resistance to the drug. 
Certain modes of resistance that have been identified include a decrease in cellular 
accumulation, an increase in DNA repair by NER, and increased detoxification in the 
cytoplasm by glutathione (GSH) (14-16). The tripeptide GSH is the most prevalent 
intracellular non-protein thiol which is used as a defense against toxins and oxidants. 
Coordination of GSH to platinum via thiols leads to the deactivation of the platinum (16). 
Interestingly enough, GSH is a good reducing agent for reducing inactive platinum(IV) 
pro-drugs to active platinum(II) species (17).  
Second and Third Generation Platinum Design. Over 3000 cisplatin analogues 
have been prepared, and their cytotoxicities evaluated (18) (Figure 1.1). trans-
Diamminedichloroplatinum(II), the geome tric isomer of cisplatin, is clinically inactive 
(5). Most compounds follow the structure-activity relationships that Cleare and 
Hoeschele summarized in the 1970’s. These state that for a platinum(II) or platinum(IV) 
analogue to be effective it must follow the general form cis-[PtX2(Am) 2] or cis-
[PtX2Y2(Am) 2], whereby X is a leaving group with intermediate binding strength, and 
Am is an inert amine with one or more NH moieties (19, 20). Carboplatin and Oxaliplatin 
are two drugs that follow this strategy and have been approved by the FDA.  
With the increase in understanding of how cisplatin kills, different strategies 
emerged to try and increase cytotoxicity. One such strategy is to use a sterically hindered 
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amine. The idea is that if the axial position above the platinum(II) plane is blocked, 
substitution reactions would be suppressed and cellular detoxification by GSH would be 
limited (10). Another strategy is to make platinum(IV) derivatives which would be more 
stable, and in general will have a greater water solubility. Platinum(IV) is reduced to 
platinum(II) in the cell cytoplasm, followed by aquation and DNA binding (10). 
Alternatively, biomolecules can be tethered to platinum(II) or platinum(IV) to directly 
target or increase the potency of the platinum to cancer cells. DNA intercalators, amino 
acids, sugars, and hormones are all examples of biomolecules that have thus far been 
tethered to platinum (10, 21).  
Herein we discuss the synthesis of novel platinum(IV) compounds capable of 
tethering biomolecules and the linking of two biomolecules to platinum(IV). Carboplatin 
has different kinetic properties than cisplatin. Platinum(IV) derivatives that are capable of 
conjugating biomolecules and reduce to give carboplatin in the cell cytoplasm were 
developed. We then tethered estrogen to a novel carboplatin derivative to sensitize certain 
breast cancer cells towards the platinum. Recent work in our lab has shown that the 
linkage of estrogen to an oxidized derivative of cisplatin can sensitize certain cells 
towards platinum treatment (21). Finally, we conjugated folic acid to platinum(IV) 
cisplatin and carboplatin derivatives to increase cellular targeting of platinum. Folic acid 
is an essential biomolecule for cell replication and, not surprisingly, cancer cells 
overexpress folic acid receptors.  
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Figure 1.1. Structures of some platinum compounds, including cisplatin and its clinically 
inactive isomer, trans-DDP. Carboplatin and oxaliplatin are second generation drugs that 
have been approved by the FDA. JM216 and iproplatin are platinum(IV) compounds that 
have received much attention, and ZD0473 was designed to sterically cap the platinum. 
Cisplatin succinate is currently used to link biomolecules.  
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Chapter Two: 
 
Synthesis and Characterization of Carboplatin Derived Platinum(IV) 
Compounds Capable of Conjugating Biomolecules 
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Introduction 
Recent work in our lab has focused on the attachment of biomolecules to an 
oxidized derivative of cisplatin to improve platinum-based chemotherapy by selectively 
targeting cancer cells (1, 2). Carboplatin, cis-
diamminecyclobutanedicarboxylatoplatinum(II),  is a second generation drug that has 
different substitution kinetics than cisplatin (3). Having a platinum(IV) compound with 
tethered biomolecules that will be reduced to give carboplatin is desirable. The slower 
kinetics of carboplatin could be exploited to allow certain slow-acting biomolecules to 
react, and use of the carboplatin platform expands the options for development of 
platinum(IV) conjugates. 
Current methodology used to tether biomolecules to cisplatin does not afford 
much flexibility in the number of targeting moieties attached to the platinum(IV). 
Because cis,cis,trans[PtCl2(NH3)2(succinate)2] (Figure 2.1) has two carboxyl groups 
trans to one another, coupling to an amine results in either the mono- or bis- substituted 
product. Modification of the coupling reagents and conditions allows for some selectivity 
for either mono- or bis- substituted products, however, a mixture of products is often 
obtained. Synthesis of a mono- conjugate is desirable because it might have better water 
solubility, and would decrease the steric bulk of the platinum compound, facilitating 
diffusion into the cell and subsequent reactions that cleave the biomolecule from the 
platinum center. 
Herein we report the synthesis and characterization of carboplatin derived 
platinum(IV) compounds that can bind either one or two biomolecules selectively (Figure 
2.2). 
 18 
 
Experimental Procedures 
General Considerations. Potassium tetrachloroplatinate(II) was a gift from 
Engelhard. Carboplatin was prepared as described in the literature (4). All chemicals and 
solvents were purchased from commercial sources. 1H and 195Pt NMR spectra were 
collected on a Varian 300 and Varian 500 MHz spectrometers at the MIT Department of 
Instrumentation Facility (DCIF). All 195Pt NMR was referenced to a standard of K2PtCl4 
in water at d = -1631. Reverse phase HPLC was carried out on a Waters pump and 
absorbance detector, and peaks were detected at 254 nm unless otherwise noted. LCMS 
and ESI-MS was performed on an Agilent 1100 Series LC/MSD Trap. X-ray 
crystallography was carried out on a Siemens diffractometer in our lab. 
Synthesis of cis, cis, trans-diammine-cyclobutanedicarboxylato-
dihydroxyplatinum(IV) (hydroxy carboplatin). Carboplatin (2.36 g, 6.36 mmol) was 
slowly added to 22 mL of 15% hydrogen peroxide in water. The reaction was stirred in 
the dark for 2 h at 70 oC, and for an additional 30 min at 60 oC. The pale yellow 
suspension that formed was cooled to room temperature and centrifuged to afford a white 
solid (yield: 0.74 g, 1.8 mmol, 28.7%). The remaining solution was lyophilized, giving a 
second crop (yield: 1.10 g, 2.7 mmol, 42.7%). 1H NMR (d6-DMSO, 300 MHz): d 1.7 (m, 
2H, CH2), 2.5 (m, 4H, CH2), 5.5 (bs, 6H, NH3), 10.2 (s, 2H, OH).  
Synthesis of cis, cis, trans-diamminecyclobutanedicarboxylate-
disuccinateplatinum(IV) (carboplatin succinate). Hydroxy carboplatin (1.75 g, 4.32 
mmol) and succinic anhydride (1.73 g, 17.3 mmol) were added to 25 mL of DMSO. The 
solution was heated to 70 oC and stirred for 2.5 h, giving an amber solution. 
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Lyophilization removed most of the DMSO, resulting in a soft, yellow solid. The product 
was precipitated out of the remaining DMSO by rinsing 3 times with 50% ether in 
acetone (20 mL total). The off-white powder was dried in vacuo (yield: 1.60 g, 2.6 mmol, 
61.2%). The ether and acetone supernatants were combined and cooled to –20 oC, upon 
which more product precipitated out. The solid was isolated by centrifugation, and dried 
in vacuo (yield: 0.35 g, 0.58 mmol, 13.4%). 1H NMR (d6-DMSO, 300 MHz): d 1.8 (m, 
2H, CH2), 2.2-2.6 (m, 12 H, CH2), 6.4 (bt, JH-N = 50.25 Hz, 6H, NH3), 12.1 (s, 2H, OH). 
195Pt NMR (H2O, 500 MHz): d 1893 (m, JPt-N = 250 Hz). MS (ESI) calculated for [M + 
Na]+ 628.3, found 628.0 amu.  
Synthesis of cis, cis, trans-Diammin-cyclubutanedicarboxylato-
diacetateplatinum(IV) (carboplatin acetate). A suspension of hydroxy carboplatin (0.10 
g, 0.25 mmol) in acetic anhydride 2.5 mL was stirred at room temperature for 1 h. The 
reaction was diluted with an additional 6 mL of acetic anhydride and heated to 50 oC. 
After 3 h, the solution was cooled to –20 oC, rinsed with ether, and the white solid 
isolated by centrifugation was dried in vacuo (yield: 0.08 g, 0.163 mmol, 66.2%). The  
mother liquor was diluted with ether, and cooled to –20 oC overnight, and centrifugation 
gave a second crop (0.03 g, 0.061 mmol, 24.8%). 1H NMR (d7-DMF, 300 MHz): d 1.8 (s, 
6H, CH3), 1.9 (m, 2H, CH2), 2.6 (t, 4H, CH2), 6.8 (m, JH-N = 41.25 Hz, JH-Pt = 66.7 Hz, 
6H, NH3). 195Pt NMR (DMF, 500 MHz): d 1923.  
Synthesis of cis, cis, trans-
diamminecyclobutanedicarboxylatehydroxyacetateplatinum(IV) (carboplatin 
monoacetate). A suspension of hydroxy carboplatin (0.04 g, 0.099 mmol) in 8 mL of 
methanol was prepared, and acetic anhydride (10.0 µL, 0.099 mmol) added. The reaction 
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was allowed to stir overnight, before centrifugation isolated the precipitate. The solid was 
rinsed with ether and dried in vacuo. 1H NMR (d7-DMF, 300 MHz): d 1.8 (s, 6H, CH3), 
1.9 (m, 2H, CH2), 2.5 (t, 2H, CH2), 2.6 (t, 2H, CH2), 6.3 (m, JH-N = 40.5 Hz, JH-Pt = 55.0 
Hz,  6H, NH3). MS (ESI) calculated for [M-H]- 446.4, found 446.0 amu.  
 
Synthesis of cis, cis, trans-
diamminecyclobutanedicarboxylatehydroxysuccinateplatinum(IV) (carboplatin 
monosuccinate). A suspension of hydroxy carboplatin (0.10 g, 0.247 mmol) was stirred in 
3 mL DMSO. Succinic anhydride was dissolved in 1 mL DMSO, and added dropwise 
over 2 min to the hydroxy carboplatin suspension. The reaction stirred at room 
temperature for 24 h before centrifugation and lyophilization of the solution to give a 
white solid. The product was recrystallized by vapor diffusion of acetone into an aqueous 
solution. 1H NMR (d6-DMSO, 300 MHz): d 1.6 (m, 2H, CH2), 2.2-2.6 (m, 8H, CH2), 5.87 
(m, JH-N = 53.7, 6H, NH3). 195Pt NMR (DMSO, 500 MHz): d 1751.  MS (ESI) calculated 
for [M + Na]+ 528.3, found 528.0 amu.  
Crystallization and X-Ray Crystal Structure of Hydroxy Carboplatin. Hydroxy 
carboplatin (1.00 g, 2.47 mmol) was dissolved in boiling water (33 mL). The solution 
was cooled to 4 oC, and white crystals were allowed to grow over three days. X-ray 
crystallographie data were collected, and the structure was solved by Sumi 
Mukhopadhyay (Figure 2.3).  
 
Results and Discussion. 
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Synthesis of Characterization of Hydroxy Carboplatin. Carboplatin is readily 
oxidized by hydrogen peroxide to give a platinum(IV) species. Because 
cyclobutanedicarboxylic acid (CBDCA) is a better donor of electron density than 
chloride ions, the reaction is more vigorous than the oxidation of cisplatin. The reaction is 
not clean, with roughly 5% of the platinum forming a byproduct. Because the impurity is 
only detectable in the chemical shift of the ammines in the proton NMR, it is believed to 
be the aquated species of carboplatin, whereby the CBDCA is replaced by two 
equivalents of water or OH. Although the half life for carboplatin in water is 8 hours (5), 
the heat that forms in the reaction could increase the rate of substitution. Hydroxy 
carboplatin is isolated by recrystalization from a supersaturated aqueous solution, or by 
vapor diffusion of acetone into an aqueous solution to give colorless needle crystals. The 
structure of hydroxy carboplatin was determined by X-ray crystallography, which shows 
that the two hydroxo groups are trans to each other in axial positions. The Pt-O-C-C-C-O 
ring of the CBDCA ligand lies flat in the equatorial plane, with the cyclobutane ring lying 
in a plane perpendicular to the ring containing the platinum. Although the oxidized 
product is not readily soluble in any organic solvent, a low quality proton NMR was 
obtained which revelaed and shows that the ammines are shifted downfield relative to 
those in carboplatin, reflecting the lower electron density around the platinum center.  
Synthesis and Characterization of Carboplatin Succinate. Hydroxy carboplatin 
readily reacts with two equivalents of succinic anhydride, giving carboplatin succinate 
cleanly. The product has two acid moieties, which can be used to conjugate the platinum 
to amines. Several attempts were made to grow crystals, including vapor diffusion of 
acetone, methanol, and ethanol into an aqueous solution. All trials resulted in either no 
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solid formation or rapid formation of a fine powder. In order to slow the nucleation, 
evaporation from a saturated aqueous solution and cooling of a supersaturated solution 
were also attempted. Both of these trials resulted in no crystal growth, despite taking up 
to a week to begin precipitating out of solution. Despite the lack of structural evidence for 
carboplatin succinate, mass spectroscopy showed the product peak, and 195Pt and 1H 
NMR showed that the carboplatin succinate was pure. The ammine shift in the proton 
NMR is very sensitive to the environment of the platinum thus reflects purity. The 
ammine protons are coupled to the nuclear spins of both 14N (I = 1) and  195Pt (I = ½, 33 
% abundance) resulting in an overlapping triplet and quartet. When the platinum(IV) 
species is pure, this pattern is clearly visible and symmetric. Impurities result in the 
merging of the peaks into a broad singlet. The splitting is more readily seen in DMF than 
DMSO, possibly because DMSO can bind to the platinum center. 
Synthesis of Platinum(IV) Mono-Substituted Compounds. The neat conversion of 
hydroxy carboplatin to carboplatin succinate inspired the exploration of the scope of this 
reaction, and mono-substituted platinum(IV) compounds were prepared. Carboplatin 
monosuccinate was prepared using more dilute reaction mixtures, stirring at room 
temperature, and adding the anhydride dropwise. The insolubility of hydroxy carboplatin 
in DMSO afforded a way to separate it from the product solution. When carried out on a 
small scale, LCMS and proton NMR confirmed that no dicarboxylate product was 
formed.  
Carboplatin monoacetate was prepared under similar conditions as carboplatin 
monosuccinate with the intent of being able to react it with one equivalent of succinic 
anhydride to give a “capped” platinum(IV)  carboplatin derivative that could link one 
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biomolecule (3 in Figure 4.3). Because reduction potentials are very sensitive to the trans 
axial ligands, a “capped” monosuccinate will have different reduction properties than the 
carboplatin monosuccinate prepared (6). As a comparison, carboplatin acetate was also 
prepared.  
Despite confirmation of pure carboplatin monosuccinate and carboplatin 
monoacetate by LCMS, when the reactions were scaled up only 80-95 % of the isolated 
product was mono-substituted. HPLC was attempted to purify the compounds, and 
unfortunately, our species decomposed on the column. Currently, recrystallization trials 
are underway for both carboplatin monosuccinate and carboplatin monoacetate; moderate 
success at purification of the monosuccinate has been achieved by vapor diffusion of 
acetone into an aqueous solution of carboplatin monosuccinate. 
Characterization of the Mono-substituted Platinum(IV) Compounds. Evidence for 
the synthesis of the mono substituted platinum(IV) compounds comes from MS and 
NMR spectroscopy. ESI-MS gave the molecular ion peak with an isotope pattern that 
matches the calculated pattern (Figure 2.4). Furthermore, protonation of the hydroxyl 
groups followed by fragmentation gives a distinct [M-OH]+ fragment that is visible only 
in the monosubstituted compounds. 195Pt NMR spectroscopy of carboplatin 
monosuccinate revealed that it is shifted ~150 ppm downfield when compared to 
carboplatin succinate. The ammine shift in the proton NMR is also between hydroxy 
carboplatin and carboplatin succinate. Both of these observations are consistent with the 
notion that hydroxy carboplatin has the greatest electron density about the platinum 
center, and the platinum(IV) di- carboxylates have the lowest electron density about the 
platinum center. The trend in proton NMR ammine shifts is observed in both the acetate 
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and succinate series of platinum(IV) compounds. Additional 195Pt NMR needs to be done 
to confirm the trend in the other platinum(IV) derivatives.   
The 1H NMR of carboplatin monoacetate is interesting, for it reveals that certain 
protons that are equivalent in both hydroxy carboplatin and carboplatin acetate are in 
different chemical environments in the carboplatin monoacetate. This effect is most 
pronounced in the CH2 protons of the cyclobutane ring that are a- to the di- carboxylate. 
The crystal structure reveals that the cyclobutane ring is perpendicular to the N-Pt-N 
plane (Figure 2.3). This feature results in one methylene pointing towards the hydroxo 
ligand, and the other pointing towards the carboxylate. Because of this asymmetry, the 
two a- methylene groups have distinct chemical shifts; the increased symmetry in 
carboplatin acetate gives rise to a single triplet (Figure 2.5).  
In both carboplatin succinate and carboplatin acetate, the ammine signal in the 
proton NMR is shifted significantly downfield compared to the ammine of hydroxy 
carboplatin. This result indicates that the ammine protons are more deshielded in the 
carboxylate complexes. The change in signal can be a probe for the electron density 
around the platinum(IV) center. Because water has a higher pKa than carboxylic acids, 
the hydroxide anion is less stable and donates more electron density to the platinum(IV). 
This effect makes the platinum(IV) center more electron rich, and through inductive 
effects, shields the ammine hydrogens. Because carboxylic acids have a lower pKa, and 
are more electron withdrawing due to resonance, the carboxylate is more stable and 
donates less electron density to the platinum center. The chemical shift for the amines in 
the monocarboxylates lies between that of the dicarboxylates and hydroxy carboplatin. 
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The result is that the platinum takes more electron density from the ammines, deshielding 
the proton NMR signal (Figure 2.6).  
This insight gives us an indication of the reduction potentials of the mono-
carboxylates prepared. It is well documented in the literature that the reduction potentials 
of platinum(IV) species depend on the axial ligands (7) and that they obey the following 
trend: -Cl > -OOCR > -OH (8). Thus, a platinum(IV) with trans chlorides is most easily 
reduced, and trans hydroxo complexes are the hardest to reduce. Because the ammine 
shift of the mono- species is between that of the platinum(IV) bis- carboxylate and the 
hydroxy carboplatin, the reduction potential should lie between that of the dicarboxylates 
and hydroxy carboplatin.  
To our knowledge the synthesis of a monocarboxylate trans to a hydroxy has been 
achieved once as a side product to a reaction (9). Although it has generally been viewed 
that trans hydroxy platinum(IV) complexes are too difficult to be reduced in the 
cytoplasm (10), recent work using XANES to determine the oxidation state of platinum 
in cells has shown that within 24 hours all of trans hydroxy platinum(IV) compounds are 
reduced to platinum(II) (7). This result suggests to us that carboplatin monosuccinate  
could be used successfully to deliver our molecule, and the lower reduction potential may 
make it less prone to reduction in the blood.  
 
Conclusion and Future Plans  
Carboplatin succinate was successfully synthesized, and has been fully characterized. 
Carboplatin monosuccinate was also prepared, although mixed products were obtained 
upon scaling up. Further attempts will be made to purify both carboplatin monoacetate 
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and carboplatin monosuccinate and subsequentially derivative them. Cytotoxicity and 
reduction potentials of the mono-carboxylates will be carried out, and compounds 1, 2, 
and 3 will be synthesized (refer to Figure 2.2). Furthermore, the analogous complexes 
using cisplatin will be prepared. This strategy will allow for the conjugation of a single 
biomolecule that has similar reduction kinetics as carboplatin succinate, and to make a 
platinum(IV) center that is conjugated with two different types of molecules. This 
approach will give our lab more flexibility in conjugating biomolecules to platinum(IV). 
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Figure 2.1. Structure of cis,cis,trans-PtCl2(NH3)2(succinate)2. 
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Figure 2.2. Synthetic scheme of carboplatin derivatives. Named complexes have been 
synthesized, and the numbered compounds are works in progress. 
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Figure 2.3. X-ray structure of hydroxy carboplatin. 
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Figure 2.4. ESI-MS of carboplatin monosuccinato showing the Pt isotope pattern.
[M + Na]+ 
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Figure 2.5. 1H NMR spectra showing the chemical shift of Ha and Hb. The increased 
symmetry in carboplatin acetate results in a single triplet, whereas the loss of a mirror 
plane gives rise to two triplets in carboplatin monoacetate. 
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Figure 2.6. The ammine region of the  1H NMR spectra of a. carboplatin monoacetate 
and 2. carboplatin acetate.  
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Chapter 3: 
 
Synthesis, Characterization, and Cytotoxicity of a Series of Estrogen-
Tethered Platinum(IV) Compounds that Reduce to Carboplatin 
 35 
Introduction 
From research delineating to the mechanism by which cisplatin may exert its 
cytotoxicity, new platinum compounds can be developed that exploit the proposed mode 
of killing. Cisplatin targets and binds DNA, forming mostly 1,2-intrastrand cross-links (1, 
2). The resulting distortions in the double helix affect DNA replication and transcription, 
and are recognized by several structure specific DNA-binding proteins including DNA 
repair and high mobility group (HMG) domain proteins (3). HMG proteins are 
architectural proteins that facilitate cellular functions involving chromosomal DNA (4), 
and there is increasing evidence that the protein plays a key role in cisplatin induced 
apoptosis. HMGB1 binds to platinum-DNA adducts, blocks nucleotide excision repair (5, 
6) and drives apoptosis. When HMG proteins are removed from cell extracts, the amount 
of repair is enhanced (7). Furthermore, overexpressing HMGB1 protein results in more 
cell death when the protein concentrations are elevated at the time of platinum damage 
(8). Thus there is a strong correlation between HMGB1 levels and DNA repair.  
The Interaction Between HMGB1 and Estrogen. HMGB1 is a structure-specific 
protein that is present in all tissues and species (9). It binds to deformed DNA structures 
that include platinum damaged sites and cruciform DNA (4), and has several functions 
(10-14) including the facilitation of binding steroid receptors to their DNA binding sites 
(15). When estrogen receptors (ER) bind to the estrogen-responsive element (ERE), the 
DNA bends (16), increasing the HMGB1 affinity. HMGB1 then binds, further altering 
the DNA structure and making a more stable receptor-DNA complex (17-19). When 
estrogen receptor positive (ER(+)) cells are treated with estrogen, an increase in HMGB1 
level is observed (20).  
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Sensitization of ER(+) Cells to Platinum(II) by Estradiol. Previous work in our 
lab has shown that cotreatment of MCF-7 cells with estrogen and cisplatin can sensitize 
these ER(+) cells by a factor of 2 (8). Repeating the experiment in HCC-1937 cells which 
lack the estrogen receptor (ER(-)) gave no heightened cytotoxicity. This finding 
prompted the synthesis of a series of estrogen tethered platinum(IV) pro-drugs that are 
reduced upon entering the cell, releasing cisplatin and two equivalents of a modified 
estrogen. The estrogen has a linker of varying length attached at the 17ß position and 
must be hydrolyzed by esterase before recognition by estrogen receptors (Figure 3.1). 
Because the kinetics of esterase depend on linker length (21), and because HMGB1 
upregulation must be optimized at the time of platinum damage, linkers of varying length 
will sensitize ER(+) cells by different amounts. Indeed, only one of the five conjugates 
made, BEP3 (Figure 3.2), showed a two-fold increase in cytotoxicity in ER(+) cells 
compared to ER(-) cells (22). Despite the success, the IC50 values for the tethered drugs 
were higher than the values obtained for cisplatin/estradiol cotreatment. 
Estrogen can also sensitize ER(+) cells to carboplatin, a second generation 
platinum(II) drug. Carboplatin has a slower rate of aquation and cells must be pretreated 
for 24 hours before estradiol treatment to show any sensitization (8). Because carboplatin 
has fewer side effects and is more widely used, and because the IC50 of BEP3 was higher 
than that of cisplatin in ER(+) cells, carboplatin analogues were synthesized with the goal 
of achieving kinetic optimization that would result in increased cell death. Herein we 
report the synthesis, characterization, and cytotoxicity of a series of estrogen-tethered 
platinum(IV) compounds that reduce to give carboplatin. 
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Experimental Procedures 
General Considerations. Potassium tetrachloroplatinate(II) was a gift from Engelhard. 
The preparation of EL1-EL5 compounds (Figure 3.3) were synthesized by methodology 
developed in our lab (22), and carboplatin succinate was made as described elsewhere in 
this work (Chapter 2). All chemicals and solvents were purchased from commercial 
sources. 1H NMR spectra were collected on a Varian 300 or Varian 500 MHz 
spectrometers at the MIT Department of Instrumentation Facility (DCIF). Mass 
spectrometry was carried out at the MIT DCIF (HRMS). Atomic absorption spectra were 
obtained on a Perkin Elmer AAnalyst 300 fitted with a graphite furnace autosampler. 
Reverse phased HPLC was carried out on a Waters pump and absorbance detector, and 
peaks were detected at 254 nm unless otherwise noted. LCMS and ESI-MS were 
performed on an Agilent 1100 Series LC/MSD Trap instrument.  
Synthesis of Mono-BOC Protected Trioxatridecanediamine (BOC-TDA). A 
solution of trioxatridecanediamine (14.11 mL, 64.2 mmol) and BOC2O (7.00 g, 32.1 
mmol) was stirred in 140 mL dioxane overnight. The solvent was removed via rotorary 
evaporation to give a colorless oil that was extracted into ethyl acetate from water. The 
organic fractions were collected and a colorless oil was isolated via rotorary evaporation 
(yield: 8.39 g, 41%). ESI-MS [M + H]+ = 321.4 (calculated), [M + H]+ = 321.4 
(observed). 
Synthesis of BOC trioxadecanediaminesuccinate (BOC-TDA-succinate) (Figure 
3.4).  BOC-TDA (2.00 g, 6.23 mmol) and succinic anhydride (0.78 g, 7.78 mmol) were 
dissolved in 24 mL of 1:1:1 pyridene: dichloromethane: acetonitrile and stirred at room 
temperature for 4 h. The solvent was removed by rotorary evaporation, and the resulting 
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oil dried in vacuo (yield: 0.25 g, 100%). 1H NMR (d6-DMSO, 300 MHz): d 1.4 (s, 9H, 
CH3), 1.6 (m, 4H, CH2), 2.2-2.5 (m, 4H, CH2), 2.9-3.1 (m, 4H, CH2), 3.4-3.6 (m, 12H, 
CH2), 6.8 (t, 1H, NH), 8.6 (t, 1H, NH), 12.05 (s, 1H, COOH).  
Synthesis of TDA-succinate-estradiol linker (EL17). BOC-TDA-succinate (0.75 g, 
1.80 mmol) and 4-DMAP (0.12 g, 1.0 mmol) were dissolved in 4 mL DMF, and DIPC 
(.016 mL, 1.0 mmol) added. After 15 min of stirring, the estradiol (0.17 g, 0.45 mmol) 
was added, and the reaction stirred at RT overnight. Dilution with 15 mL water and 
cooling to 4 oC for an hour facilitated precipitation of BOC-protected product which was 
filtered and dried in vacuo.  The solid was dissolved in 12 mL of dichloromethane and 
stirred with 1.2 mL trifluoroacetic acid for 2 h. The solvent was removed, and 10 mL 
water was added to the resulting oil. Ammonium hydroxide was added to adjust the pH to 
10.5, and the solution stirred overnight. Centrifugation afforded the isolation of a pellet 
that was dried in vacuo (yield: 0.24 g, 80%). 1H NMR (d6-DMSO, 300 MHz): d 0.80 (s, 
3H, CH3), 1.2-2.0 (m, 12H, CH/CH2/NH2), 2.0-2.45 (m, 9H, CH/CH2), 2.82 (m, 4H, 
CH2), 3.0-3.6 (m, 16H, CH2), 4.61 (t, 1H, CH), 6.95 (s, 1H, ArH), 7.0 (d, 1H, ArH), 7.35 
(d, 1H, ArH), 7.60 (t, 2H, ArH), 7.75 (t, 1H, ArH), 7.85 (m, 1H, NH), 8.15 (d, 2H, ArH). 
ESI-HRMS calculated for [M + H]+ 679.3953, found 679.3965 amu.  
Synthesis of cis, cis, trans-Diamminecyclobutanedicarboxylatebis-(17-(N-
carbonylmethylsuccinate)-estradiol-3-benzoate)platinum(IV) (BECP1). 
Diisopropylcarbodiimide (DIPC) (0.10 mL, 0.634 mmol) was added to a solution of 4-
DMAP (0.08 g, 0.634 mmol) and carboplatin succinate (0.15 g, 0.254 mmol) in 5 mL 
DMF. After stirring for 10 min at room temperature, EL1 (0.22 g, 0.507 mmol) was 
added and the reaction stirred overnight. The reaction mixture was diluted with 50 mL of 
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ether, and cooled to –20 oC for an hour to facilitate precipitation. The crude solid was 
isolated by decanting off the ether, and the product was rinsed and sonicated for 5 min in 
5 mL ethanol (3 times), 5 mL water (3 times), and methanol (1 time).  After each rinsing, 
the product was centrifuged for 3-5 min at 5000 rpm. The BECP1 was dried in vacuo to 
give a white solid (yield: 0.1717 g, 0.12 mmol, 47.0%).  1H NMR (d6-DMSO, 500 MHz): 
d 0.783 (s, 6H, CH3), 1.2-1.6 (m, 4H, CH/CH2), 1.60-1.95 (m, 10H, CH/CH2), 2.0-2.65 
(m, 14H, CH/CH2), 2.83 (m, 4H, CH2), 3.81 (d, 4H, CH2), 4.65 (t, 2H, CH), 6.32 (bt, 6H, 
NH3), 6.95 (s, 2H, ArH), 7.01 (d, 2H, ArH), 7.35 (d, 2H, ArH), 7.60 (t, 4H, ArH), 7.73 (t, 
2H, ArH), 8.12 (d, 4H, ArH), 8.31 (t, 2H, NH). ESI-HRMS calculated for [M + H]+ 
1437.5211 amu, found 1437.5208 amu.  
Synthesis of cis, cis, trans-Diamminecyclobutanedicarboxylatebis-(17-(N-(2-
carboxy-ethyl)-succinate)-estradiol-3-benzoate)platinum(IV) (BECP2). This compound 
was prepared as described for BECP1 with carboplatin succinate (0.17 g, 0.28 mmol), 4-
DMAP (0.09 g, 0.70 mmol), DIPC (0.11 mL, 0.70 mmol), and EL2 (0.25 g, 0.56 mmol) 
in 5 mL DMF. The crude BECP2 was precipitated in 50 mL ether for 1 h at –20 oC. The 
orange solid was rinsed and sonicated for 5-15 min with 10 mL ethanol (3 times), and 10 
mL boiling water (3 times). Between washes, the solid was centrifuged at 3000 rpm for 
3-5 min. BECP2 was dried in vacuo to give a white powder (yield: 0.2440 g, 0.167 
mmol, 59.3%).  1H NMR (d6-DMSO, 500 MHz): d 0.794 (s, 6H, CH3), 1.2-2.6 (m, 44H, 
CH/CH2), 2.84 (m, 4H, CH2), 3.27 (t, 4H, CH2), 4.64 (t, 2H, CH), 6.42 (bt, 6H, NH3), 
6.96 (s, 2H, ArH), 7.01 (d, 2H, ArH), 7.36 (d, 2H, ArH), 7.60 (t, 4H, ArH), 7.75 (t, 2H, 
ArH), 7.95 (m, 2H, NH), 8.11 (d, 4H, ArH). ESI-HRMS calculated for [M + Na]+ 
1487.5344 amu, found 1487.5308 amu.  
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Synthesis of cis, cis, trans-Diammine-cyclobutanedicarboxylatebis-(17-(N-(3-
carboxy-propyl)-succinate)-estradiol-3-benzoate)platinum(IV) (BECP3). This compound 
was prepared as described for BECP1 with carboplatin succinate (0.10 g, 0.165 mmol), 4-
DMAP (0.05 g, 0.413 mmol), DIPC (0.065 mL, 0.413 mmol), and EL3 (0.12 g, 0.260 
mmol) in 3 mL DMF.  The crude BECP3 was precipitated in 50 mL ether, and cooled to 
–20 oC for 1 h. The soft solid was rinsed and sonicated for 5 min with 5 mL ethanol (3 
times), and 5 mL water (3 times). Like with BECP1, the product was centrifuged between 
washes. BECP3 was dried in vacuo, affording a white powder (yield: 0.0443 g, 0.03 
mmol, 23.0%). 1H NMR (d6-DMSO, 300 MHz): d 0.801 (s, 6H, CH3), 1.0-2.0 (m, 26H, 
CH/CH2), 2.0-2.2 (m, 2H, CH), 2.2-2.6 (m, 16H, CH/CH2), 2.83 (m, 4H, CH2), 3.04 (m, 
4H, CH2), 3.26 (t, 4H, CH2), 4.64 (t, 2H, CH), 6.36 (bt, 6H, NH3). 6.96 (s, 2H, ArH), 7.01 
(d, 2H, ArH), 7.47 (d, 2H, ArH), 7.60 (t, 4H, ArH), 7.74 (t, 2H, ArH), 7.85 (t, 2H, NH), 
8.11 9d, 4H, ArH). MS (ESI) calculated for [M + H]+ 1493.5838 amu, found 1493.5856 
amu.  
Synthesis of cis, cis, trans-Diammine-cyclobutanedicarboxylatebis-(17-(N-(4-
carboxy-butyl)-succinate)-estradiol-3-benzoate)platinum(IV) (BECP4). This compound 
was prepared as described for BECP1 with carboplatin succinate (0.17 g, 0.281 mmol), 4-
DMAP (0.09 g, 0.702 mmol), DIPC (0.11 mL, 0.702 mmol), and EL4 (0.27 g, 0.562 
mmol) in 5 mL DMF. The product was purified as described for BECP2, giving a white 
powder (yield: 0.1997 g, 0.131 mmol, 46.7%).  1H NMR (d6-DMSO, 500 MHz): d 0.800 
(s, 6H, CH3), 1.2-2.6 (m, 52H, CH/CH2), 2.84 (m, 4H, CH2), 3.03 (m, 4H, CH2), 4.64 (t, 
2H, CH), 6.34 (bt, 6H, NH3), 6.96 (s, 2H, ArH), 7.01 (d, 2H, ArH), 7.34 (d, 2H, ArH), 
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7.61 (t, 4H, ArH), 7.74 (t, 2H, ArH), 7.84 (m, 2H, NH), 8.10 (d, 4H, ArH). MS (ESI) 
calculated for [M + Na]+ 1543.5970 amu, found 1543.5960 amu.  
Synthesis of cis, cis, trans-Diammine-cyclobutanedicarboxylatebis-(17-(N-(5-
carboxy-pentyl)-succinate)-estradiol-3-benzoate)platinum(IV) (BECP5). This compound 
was prepared in a similar manner as BECP1 with carboplatin succinate (0.17 g, 0.281 
mmol), 4-DMAP (0.09 g, 0.702 mmol), DIPC (0.11 mL, 0.702 mmol), and EL5 (0.27 g, 
0.562 mmol) in 5 mL DMF. The reaction was diluted with 45 mL water and cooled to 4 
oC for 1 h, before centrifugation. The remaining solid was washed with 10 mL ethanol (3 
times), and 5 mL boiling water (3 times), and dried in vacuo to give a white powder 
(yield: 0.0993 g, 0.064 mmol, 22.8%).  1H NMR (d6-DMSO, 500 MHz): d 0.801 (s, 6H, 
CH3), 1.2-2.6 (m, 56H, CH/CH2), 2.84 (m, 4H, CH2), 3.00 (m, 4H, CH2), 4.64 (t, 2H, 
CH), 6.33 (bt, 6H, NH3), 6.96 (s, 2H, ArH), 7.01 (d, 2H, ArH), 7.35 (d, 2H, ArH), 7.61 (t, 
4H, ArH), 7.75 (t, 2H, ArH), 7.81 (m, 2H, NH), 8.11 (d, 4H, ArH). ESI-MS calculated 
for [M – H]- 1547.67 amu, found 1547.0 amu. 
Synthesis of cis, cis, trans-Diammine-cyclobutanedicarboxylatebis-17-(N-
(Trioxatridecanediamine-succinic)-succinate)-estradiol-3-benzoate)platinum(IV) 
(BECP17). This compound was synthesized in a manner analogous to BECP1 using 
carboplatin succinate (0.11 g, 0.184 mmol), 4-DMAP (0.06 g, 0.460 mmol), DIPC (0.07 
mL, 0.460 mmol), and EL17 (0.25 g, 0.368 mmol) in 5 mL DMF. The reaction was 
diluted with 50 mL ether after stirring for 24 h, and cooled to -20o C for 1.5 h. The 
resulting precipitate was filtered, and rinsed three times with 4.5 mL boiling water. The 
white powder was dried in vacuo (yield: 0.15 g, 46.0%). 1H NMR (d6-DMSO, 300 MHz): 
d 0.793 (s, 6H, CH3), 1.2-2.0 (m, 24H, CH/CH2), 2.0-2.45 (m, 18H, CH/CH2), 2.45-2.50 
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(m, 12H, CH2), 2.82 (m, 8H, CH2), 3.0-3.6 (m, 32H, CH2), 4.61 (t, 2H, CH), 6.3 (bs, 6H, 
NH3), 6.97 (s, 2H, ArH), 7.0 (d, 2H, ArH), 7.35 (d, 2H, ArH), 7.62 (t, 4H, ArH), 7.75 (t, 
2H, ArH), 7.86 (m, 4H, NH), 8.15 (d, 4H, ArH). ESI-HRMS calculated for [M + Na]+ 
1949.8444, found 1949.9074 amu.  
Cell Culture Studies. MCF-7 cells were grown in DMEM (GIBCO/BRL) with 
10% FBS, 1x antibiotic/antimycotic solution (GIBCO), and 2 mM L-glutamine. HCC-
1937 cells were grown in RPMI-1640 (ATCC) containing 10% FBS and 1x 
antibiotic/antimycotic solution, 2.0 mM L-glutamine, 10 mM HEPES, 1.0 mM sodium 
pyruvate, and 2 mM glucose. All cells were incubated at 37 oC in a 5% CO2 environment. 
Absorbance were recorded on a Molecular Devices SpectraMax 340 PC at 550 nm. The 
instrument was calibrated with 0.4% sulforhodamine B in 1% acetic acid at 550 nm, and 
the linear region found to be between absorbance of 0.10 and 2.2 absorbance units.  
Overexpression of HMGB1 Induced by BECPn (n=1-5, 17) Complexes. MCF-7 
cells were grown to 70% confluence on 12 mm glass cover slips in 24 well plates. The 
cells were treated with either estradiol or BECPn in 200 nM solutions, and incubated for 
various lengths of time. The cells were then rinsed 3 x with PBS and permeabilized in 25 
% acetic acid in methanol for 10 min at room temperature, and washed 3 more times in 
PBS before treatment with a 1:100 dilution of anti-HMGB1 polyclonal antibody 
(PharMingen) for 1 h at 37 oC. The cells were subsequently washed with PBS (3 times) 
and incubated with a 1: 200 dilution of goat anti-rabbit IgG conjugated to FITC 
(Biosource International) for 1 h at 37 oC. The cover slips were washed in PBS (3 times) 
and water (2 times) before being fixed with gelvatol on microscope slides. The slides 
were incubated at 4 oC for 15 h in the dark. HMGB1 levels were visualized under a 
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fluorescent-light microscope (Diagnostic Instruments) equipped with a digital camera 
(Nikon).  
Cytotoxicity of BECPn (n=1-5, 17). The cytotoxicities of BECPn compounds 
were evaluated using the MTT assay. Briefly, 1000 cells (MCF-7) or 1,500 cells (HCC-
1937) were on a 96 well plate in 100 µL media, and incubated for 24 h. The cells were 
then treated with BECPn compound at concentrations ranging from 0 to 25 mM, and 
incubated for 96 h (MCF-7) or 144 h (HCC-1937). Cells were then treated with 20 mL of 
MTT (5 mg / mL PBS), and incubated for 5 hr. The media was removed, and the cells 
solubilized in 50-150 mL DMSO, and shaken for 5 min before reading the plates at 550 
nm.  
 
Results and Discussion 
Synthesis and characterization of BECPn (n = 1-5, 17). The preparation of carboplatin 
succinate is discussed elsewhere in this report (Chapter 2), and the carboplatin analogues 
to BECPn were prepared in a similar fashion as that described in the literature (22). Two 
equivalents of modified estrogen were allowed to react with carboplatin succinate along 
with 4-DMAP and DIPC, which are standard peptide coupling reagents. Although a 
mixture of mono- and bis- substituted platinum(IV) could be expected, proton NMR and 
mass spectrometry showed only bis- product. BECPn was purified by rinsing with hot 
water several times, followed by cold ethanol. Because ethanol removes only excess 
estrogen, and because the product has a slight ethanol solubility, a slight excess of 
carboplatin succinate was employed to ensure full reaction of estrogen. The integration of 
the amide proton H22 (Figure 3.3) to protons on the estrogen (H17) and carboplatin 
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succinate (H23) revealed the expected ratio, further indicating that no mono substituted 
product formed (Table 3.1). HPLC resulted in product decomposition to free estrogen 
linker; the decomposition was observed by collecting the product peak, rinsing the 
column, and reinjection. Proton NMR of the five compounds showed excellent 
integration of the ammine protons to those found on the estrogen, and good integration 
between the amide and succinate protons.  
Estrogen was also attached to carboplatin via a TDA-succinate linker to give an 
estrogen linker with a length of 17 atoms (Figure 3.4). TDA was first mono BOC 
protected and reacted with succinic anhydride, which was then reacted with estradiol to 
give EL17. EL17 was reacted with carboplatin as described for the other estrogen linkers, 
but had increased water solubility because of the polyether nature of the linker.  
Overexpression of HMGB1 in MCF-7 Cells Following treatment with BECPn 
(n=1-5, 17). The ability of compounds BECPn to upregulate HMGB1 was monitored via 
immunofluorescence. After cells are treated with BECPn they are incubated with a rabbit 
anti-HMGB1 antibody, followed by incubation with a FITC conjugated anti-rabbit 
antibody. This procedure allows for the visualization of HMGB1 in the cells. Because a 
24 hour pretreatment of carboplatin was needed before treatment with estradiol to see any 
effect on the cytotoxicity, we chose to look at the upregulation after 24 hours. Cells that 
were not treated serve as a negative control, while cells that are treated with estradiol for 
1.5 hours serve as a positive control. Estradiol induces the overexpression of HMGB1 
0.5-2 hours after treatment (8), and the levels remain elevated before tapering off after 24 
hours. As seen in figure 3.5, all BECPn compounds upregulate HMGB1. The degree of 
upregulation cannot be quantified via immunofluorescence, but it is clear from the 
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brightness of the cells that HMGB1 levels are still elevated after 24 hours. The behavior 
of BECPn should be analogous to BEPn, because the reduction kinetics for both should 
be very similar, giving the same modified estrogens. Incubation of BECPn for 4 hours 
showed 2-fold increase in HMGB1 levels; the same results are expected for BECPn. 
Preliminary results with shorter incubation times with BECPn show elevated levels of 
HMGB1. The ability of BECPn to induce HMGB1 overexpression indicates that the 
compounds are being taken up into the cells and that the estradiol is formed. The estradiol 
alcohol that results upon hydrolysis at the 17ß position is essential for estrogen receptor 
recognition. Assuming that the platinum center is not sterically protected, from the 
known kinetics of both platinum(IV) in vitro reduction and ester hydrolysis it is inferred 
that reduction precedes hydrolysis (21, 23).  
Cytotoxic Behavior of BECPn (n=1-5, 17) in ER(+) and ER(-) Cells.  The 
cytotoxic properties of BECP1-T were evaluated in MCF-7 and HCC-1937 cell lines, two 
human breast cancer carcinoma that are ER(+) and ER(-) respectively. Cell survival was 
evaluated with the MTT assay. In control experiments the cytotoxicity of carboplatin 
succinate was evaluated in both cell lines and was lower in MCF-7 cells, most likely due 
to increased uptake. The IC50 in MCF-7 cells was 8.45 µM and in HCC-1937 cells, 12.06 
µM. Any increase in cytotoxicity will be due to the tethered estrogen, and discrepancies 
between the cytotoxicities of the two cell lines will have to take the difference in IC50 of 
the carboplatin succinate control into consideration. As shown in table 3.2, the 
overexpression of HMGB1 in MCF-7 cells did not sensitize the cells to carboplatin. 
BECP1, BECP2, BECP4 and BECP5 all had very similar IC50 values in both cell lines 
(Figure 3.6). The cytotoxicity was increased by a factor of two for BECP4 and BECP5 
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compared to BECP1. Interestingly enough, BECP3, which had optimized kinetics for the 
cisplatin system had a significantly larger IC50 value for MCF-7 cells. BECP17 also had a 
larger IC50 value in ER(+) cells. Both of these compounds were 1.5x more toxic in ER(-) 
cells than in ER(+) cells.  
These results indicate that the kinetics of ester hydrolysis followed by HMGB1 
upregulation do not overlap with that of carboplatin aquation and DNA binding. Because 
carboplatin forms both 1,2 and 1,3 intrastrand crosslinks, and HMGB1 only recognizes 
1,2 intrastrand crosslinks (24-26), the overlap of the kinetics is more important than in 
cisplatin because there are fewer recognizable damage sites. Estradiol increases cell 
proliferation, and increases the IC50 of non-platinum-based therapeutics such as paclitaxel 
and adriamycin in ER(+) cell lines (27). It is plausible that BECPn conjugates induced 
cell proliferation. BECP3 is expected to have the fastest hydrolysis kinetics because 
BEP3 showed increased sensitivity to cisplatin in ER(+) cells. Cisplatin requires 
cotreatement with estradiol or immediate release of free estradiol to see increased 
toxicity. Although BECP17 has a longer linker and hence slower kinetics are expected, 
the more hydrophilic nature of this linker compared to the hydrophobic nature of the 
other linkers may result in a higher affinity for the esterase active site. The kinetics of 
estrogen induced cell proliferation are unknown, yet it is reasonable to assume that is it 
on the same time scale as HMGB1 upregulation because both are the result of signaling 
to the DNA.  
In both HCC-1937 and MCF-7 lines, the cytotoxicities for BECP4 and BECP5 
were significantly lower than the cytotoxicities of the shorter linkers. This effect may be 
due to increased cellular uptake; the increased lipophilicity of BECP4 and BECP4 would 
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increase passive uptake through the cell membrane; the result is similar IC50 values 
between BECP4, BECP5, and carboplatin (8). Several groups have shown in 
platinum(IV) carboxylates that the carboxylate length had a strong effect on cell uptake 
and cytotoxicity; the addition or removal of a single methylene greatly affects the 
cytotoxic properties of the compound (28-30). BECP17 had a slightly lower cytotoxicity 
in ER(-) cells compared to BECP4 and BECP5, indicating that the polyether linker may 
actually aid in cellular uptake. The increased IC50 in ER(+) cells of BECP4 hints that the 
kinetics of cell proliferation are faster than those of HMGB1 upregulation. This result is 
promising because it suggests that, if a longer linker with similar lipophilic properties can 
be prepared, ER(+) cells can be sensitized to carboplatin and be more potent than 
carboplatin alone. Work on TDA and poly(ethylene glycol) (PEG) derived longer linkers 
is underway (Figure 3.7).  Sterics along with increased entropy may affect both the 
kinetics of hydrolysis and reduction for the PEG linker, as it can fold up on itself and 
shield the platinum center.  
The failure of carboplatin estrogen conjugates to increase sensitivity of ER(+) 
cells to platinum(II) is most likely due to the failure in kinetic overlap, but other 
possibilities should be explored. Because carboplatin is hydrolyzed much more slowly 
than cisplatin, carboplatin can diffuse out of the cell more readily. Although this effect 
has been shown to be significant in other systems (31), the fact that estrogen pretreatment 
sensitized ER(+) cells to carboplatin do not make this a plausible explanation for our 
system. 
Despite the failure of BECP to heighten carboplatin sensitivity, the results of this 
study are significant in supporting the hypothesis that the kinetics of HMGB1 
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upregulation is important to platinum induced apoptosis. The discrepancy between the 
results obtained and those obtained for cisplatin show the fine line between HMGB1 
upregulation kinetics and cell proliferation kinetics. The ability of BECP4 and BECP5 to 
achieve similar IC50 to carboplatin is promising; if linkers with similar lipophilicities that 
are longer and can thus slow the kinetics of estradiol release are prepared, it might be 
possible to observe carboplatin sensitization that will result in lower IC50 than carboplatin 
treatment alone in ER(+) cells.  
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Figure 3.1. Proposed mechanism of action of platinum(IV) estradiol tethered conjugates.  
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Figure 3.2. Structure of BEP3. 
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Figure 3.5. Immunofluorescence of BECPn after 24 hour incubation. Estradiol was 
incubated for 1.5 hours prior to treatment with antibodies. Fluorescent and phase contrast 
photographs are shown. 
 control BECP1 BECP2 BECP3 
BECP4 BECP5 BECP17 estradiol 
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Figure 3.6: Graphs comparing the cytotoxicity of each BECP in both ER(+) (MCF-7) 
and ER(-) (HCC-1937) Cell lines.  
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 BECP1 BECP2 BECP3 BECP4 BECP5 BECP17 
H1 7.35 
d, 2H 
7.36 
d, 2H 
7.47 
d, 2H 
7.34 
d, 2H 
7.35 
d, 2H 
7.35 
d, 2H 
H2 7.01 
d, 2H 
7.01 
d, 2H 
7.01 
d, 2H 
7.01 
d, 2H 
7.01 
d, 2H 
7.00 
d, 2H 
H4 6.95 
s, 2H 
6.96 
s, 2H 
6.96 
s, 2H 
6.96 
s, 2H 
6.96 
s, 2H 
6.97 
s, 2H 
H6 2.84 
m, 4H 
2.84 
m, 4H 
2.83 
m, 4H 
2.84 
m, 4H 
2.84 
m, 4H 
2.82 
m, 4H 
H17 4.65 
t, 2H 
4.64 
t, 2H 
4.64 
t, 2H 
4.64 
t, 2H 
4.64 
t, 2H 
4.61 
t, 2H 
H18 0.783 
s, 6H 
0.794 
s, 6H 
0.801 
s, 6H 
0.800 
s, 6H 
0.801 
s, 6H 
0.793 
s, 6H 
H19 8.12 
d, 4H 
8.11 
d, 4H 
8.11 
d, 4H 
8.11 
d, 4H 
8.11 
d, 4H 
8.15 
d, 4H 
H20 7.60 
t, 4H 
7.60 
t, 4H 
7.60 
t, 4H 
7.61 
t, 4H 
7.61 
t, 4H 
7.62 
t, 4H 
H21 7.73 
t, 2H 
7.75 
t, 2H 
7.74 
t, 2H 
7.74 
t, 2H 
7.75 
t, 2H 
7.75 
t, 2H 
H22 8.31 
t, 2H 
7.95 
t, 2H 
7.85 
t, 2H 
7.84 
m, 2H 
7.81 
m, 2H 
7.86 
m, 2H 
H23 6.32 
bs, 6H 
6.42 
bs, 6H 
6.36 
bs, 6H 
6.34 
bs, 6H 
6.33 
bs, 6H 
6.30 
bs, 6H 
Ha 3.81 
d, 4H 
3.27 
d, 4H 
3.26 
m, 4H 
3.03 
m, 4H 
3.00 
m, 4H 
-- 
Hb 
 
-- 
 
2.84 
m, 4H 
3.04 
m, 4H 
2.84 
m, 4H 
2.84 
m, 4H 
-- 
 
Table 3.1. 1H NMR Chemical Shifts for Platinum Complexes in d6-DMSO at 25 oC.  
 60 
 
 MCF-7 HCC-1937 Cytotoxicity Ratio 
(HCC-
1937:MCF-7) 
Carboplatin 
succinate 
8.45 (0.80) 12.06 (2.83)  
BECP1 9.50 (1.81) 9.73 (1.13) 1.02 
BECP2 11.61 (1.36) 10.78 (4.17) 0.93 
BECP3 17.67 (2.47) 10.84 (2.99) 0.65 
BECP4 5.72 (1.04) 5.49 (1.29) 0.96 
BECP5 5.64 (1.18) 5.45 (0.98) 0.97 
BECPT 7.44 (1.49) 4.77 (1.01) 0.64 
 
 
Table 3.2. IC50 values in µM, for platinum(IV) Complexes.  
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Chapter 4: 
 
Targetting Cancer: Synthesis, Characterization, and Cytotoxicity of 
Folate-Tethered Platinum(IV) Conjugates 
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Introduction 
A novel strategy for exploiting the cytotoxicity of cancer therapeutics is the 
tethering of a cell-targeting moiety to a cytotoxic agent. Steroids, peptides, antibodies, 
and growth factors are examples of molecules that have thus far been attached to 
antineoplastic drugs (1-3) to increase cellular targeting while lessening the undesirable 
side effects that accompany treatment. Recent studies in our lab have shown that certain 
peptides and steroids can successfully be tethered to an oxidized derivative of cisplatin to 
give a more potent platinum compound than the parent drug (1, 2). Here we focus 
attention on folic acid, which has been used as a tumor targeting agent.  
Folic Acid and Cancer. Folic acid is an essential component in the biosynthesis of 
nucleotide bases and is also required for 1-carbon atom transfer reactions in certain 
metabolic pathways (4). It is taken into healthy cells primarily via the reduced folate 
carrier, but certain cells also express folate receptors (FR) (5, 6). Two different 
phenomena occur in cancer cells that allow us to exploit internalization by folic acid 
receptors. First, certain cancers including ovarian, uterus, brain, kidney, head and neck, 
mesothelium, and endometrium tumors (7-11) overexpress the FR by up to two orders of 
magnitude.  Interestingly enough, tumors that have survived standard chemotherapy 
regimes also have increased FR levels (12). Second, the folate receptors of malignant 
growths, unlike healthy tissue, are expressed on the cells that come into contact with 
circulating blood (4). Combined, these two factors allow us to capitalize on using folic 
acid tethered conjugates to deliver a cytotoxic agent to cancer cells. Furthermore, the 
high binding affinity of folic acid (Kd ~10-10), its ease of modification, stability, and low 
immunogenicity, make it an even more appealing targeting agent (13).  
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Uptake of Folic Acid. There are four different FR isoforms, of which only the –a  
and the –ß forms are expressed on the cell membrane. Although the details remain 
unknown, folate conjugates are taken up via receptor-mediated endocytosis (11, 14). The 
resulting endosomes are acidified (pH fluctuates between 6.9 and 4.3), prompting the 
release of the folate from the receptor (15). Opening of the cavity in the cytoplasm 
releases only 15-25% of the receptor bound folates; the remaining folate stays bound and 
is recycled back to the surface. Nonetheless, cancer cells can take up 1-2 x 105 
molecules/cell/hour (3).  
Folic Acid Anti-Cancer Conjugates. Several research groups have exploited the 
properties of folic acid to increase cytotoxicity. Manipulating folic acid by tethering 
compounds at the ? or a carboxyl allows for retention of receptor binding, although the 
latter offers reduced affinity (16). Folate coated liposomes that encapsulate anti-tumor 
drugs show increased cytotoxicity (17) and more recently conjugation to a tetraphenyl 
porphyrin afforded a more cytotoxic photosensitizer (18), both due to increased uptake. 
Folic acid has also been tethered to a platinum(II) carboplatin analogue via a 
poly(ethelyene-glycol) (PEG) linker. Despite enhanced cellular uptake, the Pt-PEG-folate 
compound showed a decrease in cytotoxicity when compared to carboplatin. The authors 
indicate that the platinum may be inactivated during the endocytosis, or that the complex 
is not readily released from the endosome due to the high molecular weight of PEG (19).  
The use of platinum(IV) in the design of novel folate tethered agents is more 
appealing than the use of platinum(II) because of greater kinetic inertness, which  should 
increase the resilience of the compound throughout receptor mediated endocytosis. Since 
cancer cells have a reducing environment (21, 22), both folate and platinum(II) will be 
 64 
released once the prodrug enters the cell (Figure 4.1). Here we describe the synthesis and 
early characterization and cytotoxic profile of such conjugates.  
 
Experimental Procedures 
General Considerations. Potassium tetrachloroplatinate(II) was a gift from Engelhard. 
Carboplatin and cisplatin succinate were prepared as described in the literature (1) and 
elsewhere in this work. All chemicals and solvents were purchased from commercial 
sources. 1H NMR spectra were collected on a Varian 300 MHz spectrometer at the MIT 
Department of Instrumentation Facility (DCIF). ESI-HRMS was carried out at the MIT 
DCIF. Reverse phase HPLC was run with a Waters pump and absorbance detector, and 
peaks were detected at 254 nm unless otherwise noted. LCMS was performed on an 
Agilent 1100 Series LC/MSD Trap instrument. Atomic Absoption spectra were obtained 
on a Perkin Elmer AAnalyst 300 fitted with a graphite furnace autosampler. UV/VIS was 
performed on a Hewlett Packard 8453 spectrometer. Unless otherwise noted, all reactions 
involving folic acid or a folic acid derivative were run and worked up in the dark.  
Mono-BOC protection of poly(ethylene glycol)-bis-amine (BOC-PEG) (Figure 
4.2). Poly(oxyethelene)-bis-amine (2.53 g, 0.755 mmol) with an average molecular 
weight of 3,350 was dissolved in 40 mL 50% aqueous 1,4-dioxane and di-tert-
butyldicarbonate (BOC2O) (0.0824 g, 0.378 mmol) was added. The reaction stirred 
overnight and the solvent removed by rotorary evaporation to yield a white solid (yield: 
2.61 g, 100%). 
Synthesis of NH2-PEG-Folate. Folic acid (0.0524 g, 0.119 mmol) was dissolved 
in 5 mL DMSO, and DCC (0.0221 g, 0.107 mmol) along with pyridine (8.0 µL, 0.101 
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mmol) was added, and the reaction allowed to stir for 5 min. This activated folic acid 
solution was added dropwise to BOC-PEG (0.134 mmol) in 2 mL DMSO, and the 
reaction was stirred overnight at room temperature in the dark. The product was isolated 
by washing twice with 40 mL 30% acetone in ether, followed by centrifugation. The 
resulting white solid was dissolved in water, and purified by reverse phase HPLC. The 
product was then BOC deprotected by stirring in 2 N HCl overnight, before being dried 
(yield: 0.0423 g, 0.011 mmol, 10.4%).  1H NMR (d6-DMSO, 300 MHz): d 8.66 (s, 1H, 
ArH), 8.20 (d, 1H, NH), 7.62 (d, 2H, ArH), 7.21 (t, 1H, NH), 6.62 (d, 2H, ArH), 4.45 (s, 
2H), 4.30 (m, 1H, CH), 3.33 (bs, PEG), 2.20 (m, 4H, CH2). 
Synthesis of Mono-BOC protected trioxatridecanediamine (BOC-TDA). A 
solution of trioaxatridecanediamine (14.11 mL, 64.2 mmol) and BOC2O (7.00 g, 32.1 
mmol) was stirred in 140 mL dioxane overnight. The solvent was removed via rotorary 
evaporation to give a colorless oil that was extracted into ethyl acetate from water. The 
organic fractions were collected and a colorless oil was isolated via rotorary evaporation 
(yield: 8.39 g, 41%). ESI-MS [M + H]+ = 321.4 (calculated), [M + H]+ = 321.4 
(observed). 
Synthesis of Trioxatridecanediamine-folate (TDA-folate). DCC (0.52 g, 2.52 
mmol) and pyridine (189 uL, 2.39 mmol) were added to a solution of folic acid (1.17 g, 
2.65 mmol) in 100 mL DMSO. After stirring for 15 min, BOC-TDA (1.70 g, 5.30 mmol) 
was added, and the reaction stirred 24 h in the dark. The solvent was removed in vacuo, 
and the remaining orange solid rinsed with 30% acetone in ether, and collected by 
centrifugation. The BOC protecting group was removed by stirring overnight in 100 mL 
10% TFA in dichloromethane. The solvent was removed, and the remaining oil dissolved 
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and stirred in an aqueous solution of ammonium hydroxide (pH 9) for 2 hours, before 
being dried in vacuo to give a yellow solid (yield: 0.75 g, 48.7%). 1H NMR (d6-DMSO, 
300 MHz): d 8.63 (s, 1H, ArH), 7.85 (m, 1H, NH), 7.6 (m, 3H, ArH and NH), 7.0 (bt, 1H, 
NH), 6.63 (d, 2H, ArH), 4.49 (d, 2H, CH2), 4.2 (m, 1H, CH), 3.33 (m, 18H, CH2), 2.81 (t, 
2H, CH2), 1.5-2.0 (m, 4H, CH2). ESI-HRMS [M + H]+ = 644.3151 (calculated), [M + 
H]+= 644.3165 (observed). 
HPLC Monitoring of CPG-Mediated Cleavage. Carboxypeptidase-G (CPG) 
digestion was carried out as described in the literature (20). Briefly, 0.5 mL of a 0.1 
mg/mL folic acid derivative solution in Tris buffer (pH = 7.3) was incubated with either 
½ unit enzyme (in 250 µL) or 250 µL Tris for 24 h at 30 oC. The peak area of the 
derivatives was monitored by HPLC (100% water to 50% water: 50% acetonitrile over 30 
min) at both ? = 254 and ? = 280 nm.  
FITC conjugation of TDA folate. TDA Folate (33 mg, 0.051 mmol) and FITC (20 
mg, 0.051 mmol) were stirred in 5 mL DMF overnight in the dark. The reaction was 
monitored by LCMS, and 75 mg of TDA folate was added to drive the reaction to 
completion after the initial 24 h. The product was isolated by lyophilization to give a dark 
amber solid (yield: 0.095 g, 100%). [folate] / [FITC] = 3.65 by UV/VIS (e282= 22,600 M-
1cm-1  (folate), e494= 68,000 M-1cm-1 (FITC)).  
Synthesis of Platinum(IV) cisplatin bis PEG Folate (Pt-PEG-folate). Cisplatin 
succinate (0.0069 g, 0.016 mmol), 4-DMAP (0.0040 g, 0.033 mmol), and DIPC (5.1 uL, 
0.033 mmol) were dissolved in 1 mL of DMF, and allowed to stir for 15 min. A solution 
of PEG Folate (0.1110 g, 0.029 mmol) in 1 mL DMF was added to the activated 
succinate solution, and the reaction stirred overnight. Crude product was isolated by 
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adding 50 mL of ethyl ether and cooling the solution to -20 oC for 2 h. The yellow solid 
was isolated via centrifugation and dialyzed several times in water. The resulting solution 
was lyophilized, yielding a pale yellow solid (yield: 0.0032 g, 3%).  
Synthesis of Platinum(IV) cisplatin monofolate (PMF). EDC (0.0851 g, 0.444 
mmol), NHS (0.0511 g, 0.444 mmol), and cisplatin succinate (0.0963 g, 0.222 mmol) 
stirred in 10 mL of water for 10 min before the addition of TDA folate (0.1070 g, 0.167 
mmol) in 10 mL water. The reaction stirred overnight, and the reaction solution dialyzed 
against 5 mM sodium bicarbonate buffer (pH 9.0) and water to remove unreacted starting 
material and salt, respectively. The removal of both platinum and folate starting material 
was monitored by reverse phase HPLC. The water was removed by lyophilization to give 
a yellow powder that contained trapped water (yield: 0.177 g, 91 %). 1H NMR (d6-
DMSO, 300 MHz): 7.20 (m, NH, 1H). ESI-HRMS [M + H]+= 1160.2970 (calculated), 
[M + H]+= 1160.2954 (observed). 
Synthesis of Platinum(IV) cisplatin bis folate (PBF). EDC (0.064 g, 0.337 mmol), 
HOBt (0.0455 g, 0.337 mmol), and cisplatin succinate (0.0487 g, 0.112 mmol) was 
stirred for 10 min in 10 mL DMF before a solution of TDA folate (0.1082 g, 0.168 mmol) 
in 15 mL DMF was added. The reaction stirred overnight. The solution was diluted with 
50 mL water, and dialyzed as described for cisplatin monofolate. The product was dried 
to give an insoluble, unionizeable yellow powder. 
 
Synthesis of Platinum(IV) carboplatin monofolate (CPMF). Carboplatin succinate 
(0.0408 g, 0.067 mmol), 4-DMAP (0.0247 g, 0.202 mmol), and DIPC (31.3 µL, 0.202 
mmol) were dissolved in 10 mL of DMF at 0 oC. After stirring for 10 min, a solution of 
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TDA folate (0.13 g, 0.202 mmol) in 30 mL DMSO was added dropwise over 15 min, and 
the reaction was allowed to warm up to room temperature. After stirring overnight, the 
amber product was precipitated by adding 25% acetone in ether (200 mL) and cooling to 
-20 oC for 2 hours. The product was dissolved in 5 mL DMSO and diluted with 20 mL 
water, and dialyzed as described for cisplatin monofolate. The product was dried to give 
an insoluble, unionizeable yellow powder. 
Cell Culture Studies. HeLa cells were grown in RPMI-1640  (ATCC) 
supplemented with 10% FBS, 1x antibiotic/antimycotic solution (GIBCO), 2 mM L-
glutamine, 10 mM HEPES, and 1.0 mM sodium pyruvate. Folate free media was 
prepared with RPMI-1640 (folate free) (GIBCO) supplemented with charcoal-dextran 
treated FBS, 1x antibiotic/antimycotic solution (GIBCO), 2 mM L-glutamine, 10 mM 
HEPES, and 1.0 mM sodium pyruvate. Cells designated as HeLa FA- were HeLa cells 
grown for one passage in folate-free media, and subsequent experiments carried out in 
folate free media. All cells were incubated at 37o C in a 5% CO2 environment. 
Absorbances were recorded on a Molecular Devices SpectraMax 340 PC at 550 nm. 
Cytotoxic Profile of Platinum(IV) Tethered Folate Compounds. The cytotoxicity 
of the made compounds were evaluated using the MTT assay. A quantity of 1000 HeLa 
and HeLa FA- cells were seeded in 100 mL onto a 96 well plate and incubated for 24 h. 
The cells were then treated with the platinum(IV) compound at concentrations ranging 
from 0 to 25 mM and incubated for 96 h. Cells were then treated with 20 mL of MTT (5 
mg / mL PBS), and incubated an additional 5 h. The media was removed, and the cells 
solubalized in 200 mL DMSO, and shaken for 5 min before reading the plates at 550 nm.  
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Results and Discussion. 
Synthesis and Characterization of Folate Linkers. In order to link folic acid to our 
oxidized platinum(IV) succinate species, a diamine was needed. Initial trials in our lab to 
tether platinum(IV) to folate via an ethylenediamine linker failed because of the low 
solubility of the ethylenediamine-folate. Tethering a mono-BOC protected ethylene 
diammine to the platinum(IV) was successful, but unfortunately the BOC deprotection in 
hydrochloric acid resulted in decomposition. In order to increase the solubility, a linker 
that had ether groups was desired. Synthesis of PEG-folate was reported in the literature, 
and we decided to apply the methodology to our Pt(IV) conjugates. However, the steric 
properties of PEG made purification difficult and, as a result, we also chose to focus on a 
shorter linker, namely trioxatridecane-bis-diamine (TDA). This linker was successfully 
employed to tether estrogen to platinum(IV) with increased solubility. 
Following literature procedures (17, 19), PEG-folate was prepared, and analyzed 
by HPLC. Several impurities with longer retention times than free folic acid and what we 
presumed to be our product were present and because PEG does not absorb at 254 nm, it 
is believed that these peaks correspond PEG-bis-folate, and small oligomers. 
Unfortunately, our attempts to purify via dialysis and size exclusion chromatography did 
not give clean results, and we resorted to HPLC as a mode of purification.    
Synthesis of the TDA-folate was much cleaner than the PEG-folate, giving two 
products. LCMS showed that both peaks had an m / z = 644.3, indicating that the a- and 
?- conjugated product could be separated. Because conjugation at the a-carboxyl leads to 
a T-shaped compound and conjugation at the ?-carboxyl gives a linear compound, these 
different retention times are expected because of the different morphologies.  
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The isolated folate linkers were incubated with CPG which cleaves the glutamic 
residue of folic acid only if the a-carboxyl is unconjugated. After 24 h of incubation, the 
PEG-folate peak completely disappeared, indicating that the 100% of the isolated product 
was ?-conjugated. Incubation with TDA-folate resulted in the complete disappearance of 
the peak at tr = 11.8’, whereas the peak at  tr = 13.4’ was unaffected by  CPG, indicating 
that 65% was ?-conjugated. Literature values for tethered folates range from 65-85 % ?-
conjugated (18, 19).  
FITC-Conjugation to TDA-Folate. The fluorescent marker FITC was conjugated 
to TDA-folate in order to evaluate the cellular uptake into cells by fluorescent-sensitive 
techniques. Initially a 1:1 molar ration of FITC: TDA-folate was stirred in DMF, but the 
failure for the reaction to go to completion resulted in the addition of excess TDA-folate. 
The amount of FITC was compared to the amount of folate by comparing the absorbance 
at 282 nm (folate) to that at 494 nm (FITC) and a folate / FITC = 3.65. The product was 
not purified because no unreacted FITC was present. For the fluorescent-based cellular 
uptake studies excess folate will not affect the outcome of the experiments.  
Synthesis of Platinum(IV) Folates. Cisplatin succinate was employed to make 
conjugates that release cisplatin upon intercellular reduction. Pt-PEG-folate was prepared 
by using the standard peptide coupling reagents of 4-DMAP and DIPC. This combination 
tends to favor the formation of bis-substituted platinum(IV) compounds, yet a mixture of 
mono and bis substituted Pt-PEG-folate formed. Once the first PEG-folate is conjugated, 
it most likely blocks the subsequent activation or reaction at the carboxyl group that is 
attached to the platinum(IV). Size-exclusion chromatography and HPLC were both 
unsuccessful at separating the two, and dialysis was employed. Unfortunately due to the 
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constraints of the available MW cut-offs, only the minor bis-Pt-PEG-folate could be 
isolated. Concentration of bis-Pt-PEG-folate in solution was determined separately by 
AA and UV/Vis, which were in good agreement with each other. ESI-HRMS showed no 
molecular ion peak.  
After the mixture of mono and bis- folate substituted PEG platinum(IV), several 
coupling conditions were screened to determine if one form of Pt-TDA-folate could be 
made cleanly. EDC and NHS gave a greater than 90 % preference for mono-substituted 
platinum(IV), whereas DCC and HOBt gave bis-substituted product. Carboplatin 
monofolate was also prepared, and all three platinum(IV) compounds were purified by 
dialysis. Once dry, both carboplatin monofolate and cisplatin bis-folate had no solubility 
in any solvents, and neither were ionizeable by ESI-HRMS. Fortunately, cisplatin 
monofolate has solubility that is comparable to that of folic acid, and HRMS gave an m / 
z in excellent agreement to the calculated value. Crude NMR showed the formation of an 
amide at 7.2 ppm that corresponds to the successful coupling of TDA folate to the 
cisplatin succinate.  
Cytotoxicity of Pt-PEG-Folate and PMF. The cytotoxicity of Pt-PEG-Folate was 
evaluated both in normal HeLa cells, and in HeLa FR+ cells. By comparing the IC50 in 
both cell lines, we can directly see the role that the folate has on cytotoxicity (Figure 
4.3a). Treating cells with concentrations varying from 0 to 23 µM, followed by treatment 
with MTT after a 96 hour incubation resulted in no recognizable cell death in either cell 
line. Because the IC50 of cisplatin is around 1.5 µM in HeLa cells, higher concentrations 
were not evaluated because it was evident that the PEG folate was either not taken up or 
hindering platinum reduction; indeed the encumbering steric properties of PEG in 
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biological systems is not unknown (23-25). This prompted us to study folate conjugates 
with shorter linkers, namely using TDA.  
Early results of the cytotoxicity of PMF are promising (Figure 4.3b). To our 
surprise the IC50 appears to be around 0.4 µM, indicating that PMF is roughly 5 times 
more toxic than cisplatin. HeLa FA- cells were cultured in hopes of seeing increased 
uptake of PMF and thus higher toxicity. PMF must compete with folic acid for uptake, 
and this competition should result in less uptake. This has thus far not been observed, yet 
it is too early to draw conclusions. PMF is about 50 times as cytotoxic as cisplatin 
succinate. Because both PMF and carboplatin succinato or doubly negative, the 
membrane should be impermeable to both. The heightened toxicity of PMF supports the 
FR uptake hypothesis for PMF.  
 
Future Plans 
Currently, cytotoxicity and uptake studies are set up to study the uptake and 
cytotoxicity of the shorter PMF. At least ten different cell lines are going to be screened, 
and immunofluorescence studies will be done to determine which cell lines express the 
FR in excess. Because it takes at least 5 months to culture cells that overexpress folate 
receptors (26), we are focusing on showing that adding excess folate (several order of 
magnitude) will inhibit uptake and thus decrease cytotoxicity.  
 
 
References: 
 73 
1. Barnes, K. R., Kutikov, A. & Lippard, S. J. (2004) Chemistry & Biology 11, 557-
564. 
2. Mukhopadhyay, S., Barnes, C. M., Haskel, A., Levine, D., Barnes, K. R. Lippard, 
S. J. In preparation (2004).  
3. Wong, E. & Giandomenico, C. M. (1999) Chem. Rev. 99, 2451-2466. 
4. Lu, Y. & Low, P. S. (2002) Advanced Drug Delivery Reviews 54, 675-693. 
5. Nakashima-Matsushita, N., Homma, T., Yu, S., Matsuda, T., Sunahara, N., 
Nakamura, T., Tsukano, M., Ratnam, M. & Matsuyama, T. (1999) Arthritis 
Rheum. 42, 1609-1616. 
6. Turk, M. J., Breur, G. J., Widmer, W. R., Paulos, C. M., Xu, L., Grote, L. A. & 
Low, P. S. (2002) Arthritis and Rheumatism 46, 1947-1955. 
7. Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., Bagnoli, M. & Boiocchi, M. 
(1997) Int. J. Cancer 74, 193-198. 
8. Ross, J. F., Chaudhuri, P. K. & Ratnam, M. (1994) Cancer 73, 2432-2443. 
9. Weitman, S. D., Frazier, K. M. & Kamen B. A. (1994) J. Newrooncol. 21, 107-
112. 
10. Bueno, R., Appasani, K. Mercer, H., Lester, S. & Sugarbaker, D. (2001) J. 
Thorac. Cardiovasc. Surg. 121, 225-233. 
11. Turek, J. J., Leamon, C. P. & Low, P. S. (1993) J. Cell. Sci. 106, 423-430. 
12. Toffoli, G., Russo, A., Gallo, A., Cernigoi, C., Miotti, S., Sorio, R., Tumolo, S. & 
Boiocchi, M. (1998) Int. J. Cancer 79, 121-126. 
13. Reddy, J. A. & Low, P. S. (1998) Crit. Rev. Ther. Drug. Carrier Syst.  15, 587-
627. 
 74 
14. Leamon, C. P. & Low, P. S. (1991) Proc. Natl. Acad. Sci. USA 88, 5572-5576. 
15. Kamen, B. A. &Caston, J. D. (1986) Biochem. Pharmacol. 35, 2323-2329. 
16. Leamon, C. P., DePrince, R. B.  Hendren, R. W. (1999) J. Drug Target. 7, 157-
169. 
17. Lee, R. J. & Low, P. S. (1995) Biochimica et Biophysica Acta 1233, 134-144. 
18. Schneider, R., Schmitt, F., Frochet, C., Fort, Y., Lourette, N., Guillemin, F., 
Muller, J-F. & Berberi-Heyob, M. (2005) Bioorganic & Medicinal Chemistry 13, 
2799-2808. 
19. Aronov, O., Horowitz, A. T., Gabizon, A. & Gibson, D. (2003) Bioconjugate 
Chem. 14, 563-574. 
20. Gabizon, A., Horowitz, A. T., Goren, D., Tzemach, D., Mandelbaum-Shavit, F., 
Qazen, M. M. & Zalipsky, S. (1999) Bioconjugate Chem. 10, 289-298. 
21. Hall, M. D. & Hambley, T. W. (2002) Coordination Chemistry Reviews 232, 49-
67. 
22. Hall, M. D., Foran, G. J., Zhang, M., Beale, P. & Hambley, T. W. (2003) J. Am. 
Chem. Soc. 125, 7524-7525. 
23. Torchilin, V. P., Klibanov, A. L. & Huang, L. (1992) FASEB J. 6, 2716-2719. 
24. Klibanov, A. L., Maruyama, K., Beckerleg, A. M., Torchilin, V. P. & Huang, L. 
(1991) Biochim. Biophys. Acta 1062, 142-148. 
25. Mori, A., Klibanov, A. L., Tochilin, V. P. & Huang, L. (1991) FEBS Lett. 284, 
263-266. 
 75 
26. Miotti, S., Facheris, P., Tomassetti, A., Bottero, F., Bottini, C., Ottone, F., 
Colnaghi, M. I., Bunni, M. A., Priest, D. G. & Canevari, S. (1995) Int. J. Cancer 
63, 395-401. 
 76 
H+
H+
H+
H+
H+
H+
H+
internalization
endosome
acidification
endosomal release
membrane
fusion
recyling 
endosome
to nucleus
folate receptor
folic acid
linker
platinum(IV)
platinum(II)
 
Figure 4.1. Uptake and reduction of platinum(IV) folate conjugates. 
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Figure 4.2. Synthetic scheme of Pt(IV) folate conjugates. 
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c. 
Cisplatin Succinate Cytotoxicity
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Figure 4.3. a. Kill Curve of Pt-PEG-Folate, b. PMF, and c. carboplatin succinato. HeLa 
FA- is the same as HeLa FR+. 
 
